NCT04918186View on ClinicalTrials.gov

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Ovarian Cancer
Interventions
DRUG

Durvalumab

1500mg IV, 60 min day 1 every 4 weeks

DRUG

BA3011

IV

DRUG

BA3021

IV

DRUG

ENB003

IV

DRUG

Toripalimab

IV

Trial Locations (7)

60637

RECRUITING

The University of Chicago Medical Center, Chicago

V1Y 5L3

RECRUITING

BCCA - Kelowna, Kelowna

V5Z 4E6

RECRUITING

BCCA - Vancouver, Vancouver

M4N 3M5

RECRUITING

Odette Cancer Centre, Toronto

M5G 2M9

RECRUITING

University Health Network, Toronto

H2X 3E4

NOT_YET_RECRUITING

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal

H3T 1E2

RECRUITING

The Jewish General Hospital, Montreal

Sponsors

Collaborators (2)

AstraZeneca
BioAtla, Inc.
All Listed Sponsors
collaborator

Cancer Research Institute, New York City

OTHER

collaborator

AstraZeneca

INDUSTRY

collaborator

BioAtla, Inc.

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK